



Supplementary Figure 1.




Supplementary Figure 1: GNF-6231 causes no detectable toxicity in Wnt-dependent tissues. Representative (A) H&E stained sections, and (B) β -catenin immunostained sections of the colon depicted that GNF-6231 treatment had no effect on colon morphology and β -catenin protein level and localization in the tissue. (C) Representative H&E stained sections of skin from GNF-6231 or vehicle-treated animals. Scale bars in A and B equal 50 μ m. Images are representative of at least 4 sections from $N \geq 3$ mice.

Supplementary Figure 2.



Supplementary Figure 2: C-113 inhibits Wnt target gene expression. Graph showing relative Axin2 mRNA expression detected by qRT-PCR in $Sca1^+$ progenitors treated with recombinant WNT3A or with recombinant WNT3A and Wnt inhibitor C-113. Bars represent mean \pm SD. $N=3$ replicates from independent experiments; $**P\leq 0.01$ and $***P\leq 0.001$; Kruskal-Wallis test with Dunns correction for multiple comparisons.


Supplementary Figure 3.



Supplementary Figure 3: GNF-6231 causes reduction in Wnt activation in cardiomyocytes.


Representative figures showing paraffin sections from mouse hearts 7 days after MI treated with GNF-6231 (bottom panel) vs. vehicle (top panel) dual stained with anti troponin T to mark cardiomyocytes (green), anti-β-catenin (red), and DAPI (blue) to identify nuclei. Post MI, myocytes exhibit increased nuclear (active) β-catenin. Treatment with GNF-6231 virtually eliminates nuclear β-catenin in cardiomyocytes.

Supplementary Figure 4.




Supplementary Figure 4: iCell cardiomyocytes express the cardiomyocyte marker cTnI, and Wnt pathway modulation does not affect proliferation of HL-1 cardiomyocytes. (A) Representative images of iCell² Cardiomyocytes immunostained with the cardiomyocyte marker, cTnI (green). Sections were counterstained with Hoechst (blue). Scale bars equal 50 μ m. Images are representative of at least 4 sections from $N=3$ replicate cell lines. (B) Relative Axin2 mRNA expression in HL-1 mouse cardiomyocytes treated with recombinant mouse Wnt3a and/or C-113. Bars represent mean \pm SD; $N=3$ replicates from independent experiments. (C) Relative proliferation measured by BrdU incorporation by HL-1 cardiomyocytes treated with recombinant Wnt3a or Wnt3a and C-113, showing that Wnt pathway modulation did not affect their proliferation. $N=8$ replicates from independent experiments.

Supplementary Figure 5.




Supplementary Figure 5: Wnt inhibition augments proliferation of Alpha SMA negative cells in the distal myocardium, but does not affect proliferation of other fibroblast subtypes. (A) Quantification of Ki67⁺αSMA⁻ cells in the distal myocardium showing higher proportion of proliferating αSMA negative cells in GNF6231-treated hearts. $N \geq 14$ obtained from at least 4 sections imaged from $N \geq 3$ mice per group; * $P=0.0120$; Unpaired t-test. (B) Co-immunostaining for PCNA and fibroblasts marker FSP-1; quantification is presented in (C) showing no difference in percent double positive (FSP-1⁺PCNA⁺) cells between GNF-6231 and vehicle treated hearts. $N \geq 15$ obtained from at least 5 sections imaged from $N \geq 3$ mice per group; Mann-Whitney test. Representative co-immunostaining for (D) PCNA and Periostin, and (E) Ki67 and Vimentin; no significant difference in percent double stained cells between GNF-6231 and vehicle-treated sections were observed for both Periostin and Vimentin. Scale bars in B, D and E equal 50 μm.

Supplementary Figure 6.



Supplementary Figure 6: GNF-6231 treatment does not affect proliferation of vWF⁺ endothelial cells in the infarcted heart. (A) Representative vWF (red) and PCNA (green) immunostained sections of LV treated with GNF-6231 or vehicle. Sections were counterstained with Hoechst (blue); white arrows mark double stained cells. Scale bars equal 50 μ m. (B) Quantification of vWF and PCNA double positive cells showed no significant difference in percent double positive cells between vehicle and GNF-6231-treated hearts. $N \geq 20$ obtained from at least 4 sections imaged from $N \geq 5$ mice per group; $P=0.1091$; Mann-Whitney test.

Supplementary Figure 7.



Supplementary Figure 7: Conditionally immortalized mouse heart-derived Sca1⁺ cells are negative for CD31, CD45 and c-kit expression, and can upregulate myocyte, endothelial and stromal markers in specific culture conditions. (A) FACS of Sca1⁺CD31⁻CD45⁻CD117⁻ cardiac progenitor cells. (B) Images showing immunostaining for αMHC and cTnI of Sca1⁺ cells (untreated, left panels), cultured in cardiomyocyte differentiation media (middle panels) or HL-1 cardiomyocytes as control (right panel) demonstrated that conditionally immortalized murine Sca1⁺ cells retain capacity to express cardiomyocyte markers in culture. Scale bars equal 50 μm. (C) Relative gene expression of CD31 (left chart), αMHC (middle chart) and FSP-1 (right chart) in untreated Sca1⁺ cells and following culture in endothelial cell-, cardiomyocyte-, and fibroblast-specific differentiation media, respectively to demonstrate their multilineage potential. $N \geq 3$ replicates from independent experiments; * $P=0.0392$, ** $P=0.0068$, and *** $P=0.0007$; Mann-Whitney test.

Table S1. List of q-RT-PCR primers

Gene	Forward	Reverse
Axin2	GGACAGTAGCGTAGATGGAG	CGGAAAATGAGGTAGAGACA
Col1 α 1	GCCAGATGGGTCCCCGAGGT	GGGGGTCCAGCAGCACCAAC
CD31	GTGAAGGTGCATGGCGTATC	CACAAAGTTCTCGTTGGAGGT
α MHC	CCACTGTGGTGCCTCGTTC	GCGTCCGTCATTCTGTCACTC
FSP1	CGGTTACCATGGCAAGACCC	TGTGCGAAGCCAGAGTAAG
18S	CGCCGCTAGAGGTGAAATTCT	GAACCTCCGACTTTCGTTCT